25 Or More Amino Acid Residues In Defined Sequence Patents (Class 530/324)
  • Patent number: 10130692
    Abstract: The invention provides methods of formulating an anti-inflammatory composition for treating inflammatory conditions in a specific organ or tissue. The method involves selecting at least one pathogen that is pathogenic in the specific organ or tissue; producing an antigenic composition comprising antigenic determinants that together are specific for the pathogen; and formulating the antigenic composition for administration as an anti-inflammatory composition capable of eliciting an anti-inflammatory response in the specific organ or tissue. In embodiments of the invention the pathogen may be an endogenous pathogen, such as an endogenous bacterial pathogen. The pathogen may be an exogenous pathogen, such as a bacterial pathogen, viral pathogen, a fungal pathogen, or a helminth pathogen.
    Type: Grant
    Filed: January 26, 2012
    Date of Patent: November 20, 2018
    Assignee: Qu Biologics Inc.
    Inventors: Harold David Gunn, Salim Dhanji, Brett Anthony Premack, Michael Tak Huai Chow
  • Patent number: 10010614
    Abstract: The invention relates to derivatives of GLP-1 like peptides which are C-terminally extended analogs of native GLP-1. The derivatives comprise two side chains, one at a position corresponding to position 42, and one at a position corresponding to position 18, 23, 27, 31, 36, or 38, wherein both positions are when compared to GLP-1(7-37). The side chains comprise a C19, C20, or C22 diacid protracting moiety and optionally a linker. The invention also relates to intermediate products in the form of novel GLP-1 analogs incorporated in the derivatives of the invention, as well as pharmaceutical compositions and medical uses of the derivatives. The derivatives have very long half-lives while maintaining a satisfactory potency, which makes them potentially suitable for once-monthly administration.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: July 3, 2018
    Assignee: Novo Nordisk A/S
    Inventors: Steffen Reedtz-Runge, Jacob Kofoed
  • Patent number: 10005822
    Abstract: A system, including methods and compositions, for treatment of ischemia.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: June 26, 2018
    Assignee: MOREHOUSE SCHOOL OF MEDICINE
    Inventors: Roger P. Simon, Zhi-Gang Xiong
  • Patent number: 9999694
    Abstract: The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: June 19, 2018
    Assignees: Sloan-Kettering Institute for Cancer Research, Cornell University
    Inventors: Michelle S. Bradbury, Ulrich Wiesner, Oula Penate Medina, Andrew Burns, Jason S. Lewis, Steven M. Larson
  • Patent number: 9975932
    Abstract: The present invention relates to the preparation and use of recombinant variants of group 5 allergens of the Poaceae (true grasses), which are characterized by reduced IgE reactivity compared with known wild-type allergens and at the same time substantially retained reactivity with T-lymphocytes.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: May 22, 2018
    Assignee: Merck Patent GmbH
    Inventors: Martin Wald, Andreas Nandy, Helmut Fiebig, Bernhard Weber, Helga Kahlert, Gerald Reese, Oliver Cromwell
  • Patent number: 9969969
    Abstract: A process for producing plasmid DNA E. coli cells comprises a pre-culture and fed-batch process. The culture media of the batch phase and the culture medium added during the feeding phase are chemically defined. The culture medium of the feeding phase contains a growth-limiting substrate and is added, for at least a fraction of the feeding phase, at a feeding rate that follows a pre-defined exponential function, thereby controlling the specific growth rate at a pre-defined value. The process results in high yield and homogeneity of plasmid DNA.
    Type: Grant
    Filed: February 19, 2009
    Date of Patent: May 15, 2018
    Assignee: BOEHRINGER INGELHEIM RCV GMBH & CO KG
    Inventors: Hans Huber, Gerhard Weigl, Wolfgang Buchinger
  • Patent number: 9920356
    Abstract: An object of the invention is to provide a nucleic acid detection method which takes advantage of the high specificity of hybridization techniques, reduces the time length and the number of steps required for detection of PCR products, and allows for easy and highly accurate detection by visual observation without the need of special equipment; and a nucleic acid detection device or kit. The invention provides a method for detecting a target nucleic acid in a sample, which includes performing amplification of the target nucleic acid sequence to synthesize an amplification product having a partially double-stranded structure where a single-stranded region is added to each end of the target sequence, and hybridizing a nucleic acid sequence bound to a development medium and a nucleic acid sequence labeled with a labeling compound with the single-stranded regions of the amplification product to form a sandwich hybridization complex; and a detection device thereof.
    Type: Grant
    Filed: November 24, 2011
    Date of Patent: March 20, 2018
    Assignee: KANEKA CORPORATION
    Inventors: Koji Takahashi, Shigehiko Miyamoto, Takaaki Jikihara, Jun Tomono
  • Patent number: 9913878
    Abstract: Engineered peptides that bind with high affinity (low equilibrium dissociation constant (Kd)) to the cell surface receptors of fibronectin (?5?1) or vitronectin (?v?3 and ?v?5 integrins) are disclosed as useful as imaging tissue. These peptides are based on a molecular scaffold into which a subsequence containing the RGD integrin-binding motif has been inserted. The subsequence (RGD mimic) comprises about 9-13 amino acids, and the RGD contained within the subsequence can be flanked by a variety of amino acids, the sequence of which was determined by sequential rounds of selection (in vitro evolution). The molecular scaffold is preferably based on a knottin, e.g., EETI (Trypsin inhibitor 2 (Trypsin inhibitor II) (EETI-II) [Ecballium elaterium (Jumping cucumber)], AgRP (Agouti-related protein), and Agatoxin IVB, which peptides have a rigidly defined three-dimensional conformation. It is demonstrated that EETI tolerates mutations in other loops and that the present peptides may be used as imaging agents.
    Type: Grant
    Filed: January 26, 2016
    Date of Patent: March 13, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Jennifer R. Cochran, Richard H. Kimura, Aron M. Levin
  • Patent number: 9879327
    Abstract: Methods and compositions for detecting, identifying, and quantifying Brassica A genomic DNA are described. The methods are specific to the Brassica A genome and do not cross-react with other Brassica species, crops or weedy relatives that could contribute to contamination of a canola field.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: January 30, 2018
    Assignee: E. I. DU PONT DE NEMOURS AND COMPANY
    Inventors: Matthew Curtis Harmon, Nancy L Henderson, Cathy Xiaoyan Zhong
  • Patent number: 9879071
    Abstract: The application identifies novel fragments of alpha-synuclein in patients with Lewy Body Disease (LBD) and transgenic animal models thereof. These diseases are characterized by aggregations of alpha-synuclein. The fragments have a truncated C-terminus relative to full-length alpha-synuclein. Some fragments are characterized by a molecular weight of about 12 kDa as determined by SDS gel electrophoresis in tricine buffer and a truncation of at least ten contiguous amino acids from the C-terminus of natural alpha-synuclein. The site of cleavage preferably occurs after residue 117 and before residue 126 of natural alpha-synuclein. The identification of these novel fragments of alpha-synuclein has a number of application in for example, drug discovery, diagnostics, therapeutics, and transgenic animals.
    Type: Grant
    Filed: September 5, 2012
    Date of Patent: January 30, 2018
    Assignee: Prothena Biosciences Limited
    Inventors: Tamie J. Chilcote, Jason Goldstein, John P. Anderson, Donald Walker
  • Patent number: 9872919
    Abstract: The present invention provides a compound having the structure: wherein X is a therapeutic agent containing at least one amine nitrogen and the amine nitrogen on the therapeutic agent covalently bonds directly to carbon ?; Z is CH3 or CF3; R1 is —H, —NR2R3, —NH—C(?O)—R4, —NH—C(?O)—OR4, —CH2—C(?O)—NR5R6, —OR7, —CO2R7, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, or heteroaryl, wherein R2, R3, R4, R5, R6 and R7 are each, independently, —H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, an amino acid or an oligopeptide; wherein an amine of the amino acid or oligopeptide is substituted or unsubstituted; and n is an integer from 0 to 6; or a diastereomer, enantiomer or pharmaceutically acceptable salt of the compound.
    Type: Grant
    Filed: September 18, 2013
    Date of Patent: January 23, 2018
    Assignee: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventors: Nobuhide Ueki, Michael J. Hayman
  • Patent number: 9872825
    Abstract: An object of the present invention to discover a short peptide having an anti-aging effect and to provide a novel anti-aging agent comprising the peptide as an active ingredient. The inventors have discovered that a peptide consisting of an amino acid sequence ELKLIFLHRLKRLRKRLKRK (SEQ ID NO: 1) or a partial sequence thereof and having one or more effects selected from the group consisting of promoting fibroblast growth, promoting hyaluronic acid production and contracting a collagen gel, or a derivative or salt of the peptide is useful as an active ingredient of an anti-aging agent.
    Type: Grant
    Filed: March 27, 2014
    Date of Patent: January 23, 2018
    Assignee: Osaka University
    Inventors: Hironori Nakagami, Ryuichi Morishita, Hideki Tomioka, Akiko Tenma
  • Patent number: 9862837
    Abstract: The invention provided herein presents a novel family of antifouling agents based on hydroxylated and fluorinated compounds.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: January 9, 2018
    Assignee: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD
    Inventor: Meital Reches
  • Patent number: 9855312
    Abstract: Disclosed herein are compositions of GHRH agonists and peptides, and methods to treat disorders, such as ischemia and reperfusion injury. In one embodiment, a method of treating a reperfusion injury in a subject in need may involve administering a therapeutically effective amount of at least one GHRH agonist peptide to the subject. In additional embodiment, a method of promoting vasculogenesis in a mammal may involve administering a therapeutically effective amount of at least one GHRH agonist peptide to the subject. In a further embodiment, a method of promoting differentiation of mesenchymal stem cells into endothelial cells may involve contacting mesenchymal stem cells with at least one GHRH agonist peptide.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: January 2, 2018
    Assignees: UNIVERSITY OF MIAMI, THE UNITED STATES OF AMERICA, REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Andrew V. Schally, Joshua M. Hare, Norman L. Block, Samirah A. Gomes, Rosemeire M. Kanashiro-Takeuchi
  • Patent number: 9783610
    Abstract: The invention relates to variants of an antibody or antigen-binding fragment that binds specifically to an endosialin tumor endothelial marker 1 (TEM1), and prophylactic, diagnostic, and therapeutic methods using the same.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: October 10, 2017
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: George Coukos, Chunsheng Li
  • Patent number: 9758548
    Abstract: A method of treating a bacterial infection in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of a peptide being between 3 and 5 amino acids, wherein at least one amino acid of the 3 and 5 amino acids is selected from the group consisting of tryptophan, cysteine, proline and methionine.
    Type: Grant
    Filed: May 10, 2012
    Date of Patent: September 12, 2017
    Assignee: Technion Research & Development Foundation Limited
    Inventors: Noam Adir, Sharon Navon, Tali Swartzmann
  • Patent number: 9717775
    Abstract: The present invention relates to the use of compounds that block the ?9?10 subtype of the nicotinic acetylcholine receptor (nAChR) for treating pain, such as neuropathic pain and inflammatory pain, and inflammatory disorders, such as arthritis. The present invention also relates to screening compounds to identify analgesic agents that block the ?9?10 subtype of the nAChR.
    Type: Grant
    Filed: July 17, 2007
    Date of Patent: August 1, 2017
    Assignee: University of Utah Research Foundation
    Inventors: J. Michael McIntosh, Baldomero M. Olivera, Michael A. Ellison, Michelle Vincler
  • Patent number: 9700598
    Abstract: The present invention provides modified Vasoactive Intestinal Peptides (VIPs), encoding polynucleotides and vectors, as well as pharmaceutical compositions comprising the same. The invention further provides methods of making and using the modified VIP agents. In accordance with the invention the VIP exhibits an extended circulatory half-life, receptor-binding or biological potency, and/or altered receptor binding profile with respect to unmodified VIP.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: July 11, 2017
    Assignee: PHASEBIO PHARMACEUTICALS, INC.
    Inventors: Homayoun Sadeghi, Suzanne Dagher, Andrew Turner
  • Patent number: 9688742
    Abstract: The present invention relates to the general field of therapy of Inflammatory Bowel Disease (IBD) and/or Irritable Bowel Syndrome (IBS). Thus, the invention relates to a molecule selected from the trappin-2 protein or an active fraction thereof, a member of the WAP family proteins or an active fraction thereof or a member of the Serpin family proteins or an active fraction thereof for the treatment of Irritable Bowel Syndrome (IBS). The invention also relates to a recombinant food-grade bacterium comprising a gene selected from a gene coding for the trappin-2 protein or an active fraction thereof, a gene coding for a member of the WAP family proteins or an active fraction thereof, or a gene coding for a member of the Serpin family proteins or an active fraction thereof.
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: June 27, 2017
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA), UNIVERSITE PARIS DIDEROT—Paris 7
    Inventors: Nathalie Vergnolle, Jean-Michel Sallenave, Philippe Langella, Luis Bermudez-Humaran
  • Patent number: 9676823
    Abstract: A polypeptide with a predominantly hydrophobic sequence long enough to span a membrane lipid bilayer as a transmembrane helix (TM) and comprising one or more dissociable groups inserts across a membrane spontaneously in a pH-dependant fashion placing one terminus inside cell. The polypeptide conjugated with various functional moieties delivers and accumulates them at cell membrane with low extracellular pH. The functional moiety conjugated with polypeptide terminus placed inside cell are translocated through the cell membrane in cytosol. The peptide and its variants or non-peptide analogs can be used to deliver therapeutic, prophylactic, diagnostic, imaging, gene regulation, cell regulation, or immunologic agents to or inside of cells in vitro or in vivo in tissue at low extracellular pH.
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: June 13, 2017
    Assignees: Rhode Island Council on Postsecondary Education (statutory successor to Board of Governors for Higher Education, State of Rhode Island and Providence Plantations), Yale University
    Inventors: Yana K. Reshetnyak, Oleg A. Andreev, Ursula Lehnert, Donald M. Engelman
  • Patent number: 9670497
    Abstract: The invention is directed to synthetic promoter constructs for enhanced transgene expression in plants and to expression cassettes comprising the synthetic promoter constructs. The expression cassettes may include various elements for improved expression, stability of the expressed protein or efficient purification of the expressed protein, including signal sequences, protease cleavage sites for release of the target protein, trafficking peptides for trafficking of the expressed protein to various plant compartments, and/or various tags. The invention further relates to methods of expression of transgenic proteins in plants with the use of the synthetic promoter constructs and expression cassettes.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: June 6, 2017
    Assignee: AZARGEN BIOTECHNOLOGIES (PTY) LTD.
    Inventors: Mauritz Venter, Jacobus Petrus Zwiegelaar
  • Patent number: 9670254
    Abstract: The present invention relates to DNA sequences encoding Vmp-like polypeptides of pathogenic Borrelia, the use of the DNA sequences in recombinant vectors to express polypeptides, the encoded amino acid sequences, application of the DNA and amino acid sequences to the production of polypeptides as antigens for immunoprophylaxis, immunotherapy, and immunodiagnosis. Also disclosed are the use of the nucleic acid sequences as probes or primers for the detection of organisms causing Lyme disease, relapsing fever, or related disorders, and kits designed to facilitate methods of using the described polypeptides, DNA segments and antibodies.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: June 6, 2017
    Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: Steven J. Norris
  • Patent number: 9670250
    Abstract: The present invention includes a novel class of highly specific protease inhibitors. In one embodiment, the inhibitors of the invention are ?-helical in structure. In another embodiment, the present invention represents the first demonstration of a highly specific cysteine protease inhibitor.
    Type: Grant
    Filed: April 26, 2013
    Date of Patent: June 6, 2017
    Assignee: The Trustees of the University of Pennsylvania
    Inventor: Doron C. Greenbaum
  • Patent number: 9655377
    Abstract: The present invention relates to plants with increased levels of water soluble carbohydrates, particularly fructan, in the stem and leaf sheath. The present invention also provides methods of identifying and/or producing these plants. In particular, the present invention relates to a novel class of polypeptides designated MYB13 which upregulate the expression of enzymes involved in fructan synthesis. The present invention further relates to a novel promoter element that can be used to express genes predominantly in the stem and leaf sheath during the early reproductive stage of a plant.
    Type: Grant
    Filed: August 10, 2012
    Date of Patent: May 23, 2017
    Assignee: COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION
    Inventors: Gangping Xue, Cathrine Lynne Mcintyre, Maarten Christiaan Kooiker
  • Patent number: 9629895
    Abstract: An object of the present invention is to provide methods for preventing or treating a steroid-resistant or steroid-dependent inflammatory bowel disease. The object can be achieved by a method for preventing or treating a steroid-resistant or steroid-dependent inflammatory bowel disease in a patient in need of the prevention or treatment of the inflammatory bowel disease, comprises administering an effective amount of adrenomedullin, a modified product thereof having an activity of suppressing steroid-resistant or steroid-dependent inflammation, or a salt thereof having an activity of suppressing steroid-resistant or steroid-dependent inflammation, to the patient.
    Type: Grant
    Filed: January 12, 2012
    Date of Patent: April 25, 2017
    Assignee: University of Miyazaki
    Inventors: Kazuo Kitamura, Shinya Ashizuka, Haruhiko Inatsu, Toshihiro Kita
  • Patent number: 9546208
    Abstract: Modified Protein A, Protein G, Protein L, or Protein A/G that lacks antibody binding activity, and methods of the modified protein's use for purifying antibodies is provided.
    Type: Grant
    Filed: January 5, 2015
    Date of Patent: January 17, 2017
    Assignee: Bio-Rad Laboratories, Inc.
    Inventor: Mark Snyder
  • Patent number: 9540633
    Abstract: The present invention provides mutant cereal plants and mature grain thereof, characterised by enhanced levels of the enzyme phytase in the grain, and methods for inducing, detecting and selecting the mutant cereal plants. The invention further relates to animal feed comprising said grain having enhanced amounts of phytase.
    Type: Grant
    Filed: April 25, 2012
    Date of Patent: January 10, 2017
    Assignee: AARHUS UNIVERSITET
    Inventors: Henrik Brinch-Pedersen, Claus K Madsen, Giuseppe Dionisio, Preben Bach Holm
  • Patent number: 9534034
    Abstract: The present invention relates to the discovery that relaxin is associated with the development or maturation of body tissues. Knockouts of the gene encoding relaxin result in various abnormalities in the development of various tissues. The present invention provides methods of modulating apoptosis by administering a relaxin agonist or antagonist to a subject.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: January 3, 2017
    Assignee: Molecular Medicine Research Institute
    Inventors: Edward P. Amento, Chrishan S. Samuel
  • Patent number: 9535060
    Abstract: Subject of the present invention is an in vitro method for therapy follow-up in septic patients wherein the concentration of mature ADM 1-52 and/or mature ADM 1-52-Gly in a sample of bodily fluid of said septic patient is determined using an assay comprising two binders that bind to two different regions within the region of mature adrenomedullin and/or adrenomedullin-Gly that is aminoacid 21-52-amid SEQ ID No. 1 or aminoacid 21-52-Gly SEQ ID No. 2 wherein each of said regions comprises at least 4 or 5 amino acids. Subject of the present invention are further assays and calibration methods.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: January 3, 2017
    Assignee: SPHINGOTEC GMBH
    Inventor: Andreas Bergmann
  • Patent number: 9505823
    Abstract: Disclosed are fusion proteins that include albumin fused to a polypeptide that has insulin activity. The fusion proteins may include albumin fused to insulin or an insulin analog. In particular, the fusions proteins may include albumin fused to a single chain insulin analog. The fusion proteins may exhibit extended insulin activity in vivo or in vitro relative to insulin that is not fused to albumin. The fusion proteins may be formulated as aerosol compositions.
    Type: Grant
    Filed: August 7, 2007
    Date of Patent: November 29, 2016
    Assignee: TEV A Biopharmaceuticals USA, Inc.
    Inventors: Adam C. Bell, Craig A. Rosen, Indrajit Sanyal, Qinghai Zhao
  • Patent number: 9499601
    Abstract: There is presently provided a probe comprising an isolated sphingolipid binding domain (SBD) polypeptide, wherein the isolated SBD polypeptide is capable of binding to a sphingolipid, and methods and uses relating to such a probe.
    Type: Grant
    Filed: September 12, 2007
    Date of Patent: November 22, 2016
    Assignee: Agency for Science, Technology and Research
    Inventors: Rachel Kraut, Steffen Steinert, Sarita Hebbar
  • Patent number: 9492499
    Abstract: Aspects of the present invention relate to peptides having anti-inflammatory activity, compositions containing one or more of the peptides, and use of the peptides to treat conditions associated with excessive inflammation in animals, particularly humans and other mammals.
    Type: Grant
    Filed: October 13, 2015
    Date of Patent: November 15, 2016
    Assignee: Riptide Bioscience, Inc.
    Inventors: Jesse M. Jaynes, Henry W. Lopez, George R. Martin, Clayton Yates, Charles E. Garvin
  • Patent number: 9492472
    Abstract: A method of inhibiting neoplastic, cancer, and/or tumorgenic cell proliferation, cell growth and motility in a subject includes administering to a cancer cell expressing Pro-PrP and FLNa a therapeutically effective amount of a Pro-PrP regulating agent.
    Type: Grant
    Filed: December 23, 2009
    Date of Patent: November 15, 2016
    Assignee: Case Western Reserve University
    Inventors: Man Sun Sy, Wei Xin, Chaoyang Li, Shuiliang Yu, Shaoman Yin
  • Patent number: 9487560
    Abstract: This invention relates to novel synthetic lytic peptide fragments of full-length peptides with the capacity to modulate angiogenic activity in mammals. The invention also relates to the use of such peptides in pharmaceutical compositions and in methods for treating diseases or disorders that are associated with angiogenic activity.
    Type: Grant
    Filed: May 2, 2013
    Date of Patent: November 8, 2016
    Assignee: ISSAR Pharmaceuticals Ltd
    Inventor: Jesse Michael Jaynes
  • Patent number: 9475841
    Abstract: The present invention relates to a melanoma antigen peptide comprising the amino acids sequence selected in the group consisting of SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15 or a function-conservative variant thereof. Moreover the invention also relates to a melanoma antigen peptide according to the invention for use in the prevention or the treatment of melanoma in patient.
    Type: Grant
    Filed: May 22, 2012
    Date of Patent: October 25, 2016
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE D'ANGERS
    Inventors: Nathalie Labarriere, Francois Lang, Mathilde Bobinet, Anne Rogel
  • Patent number: 9434994
    Abstract: Disclosed are methods to obtain an expression score to evaluate gene expression in a tissue specimen obtained from a person having or suspected of having cancer.
    Type: Grant
    Filed: July 5, 2012
    Date of Patent: September 6, 2016
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Marileila Varella Garcia, Paul A. Bunn, Jr., Federico Cappuzzo, Wilbur A. Franklin, Fred R. Hirsch
  • Patent number: 9382297
    Abstract: A modified protein of an extracellular domain of protein A, which has the reduced ability to bind to immunoglobulin in an acidic region, compared with the wild-type extracellular domain of protein A, without impairing a selective antibody-binding activity in a neutral region. On the basis of three-dimensional structure coordinate data on a complex of the extracellular domain of protein A bound with the Fc region of immunoglobulin G, the modified protein is obtained by the substitution of amino acid residues that are located within the range of 10 angstroms from the Fc region and have a 20% or more ratio of exposed surface area, by histidine residues. Preferably, the modified protein is obtained by the substitution of amino acid residues at sites identified from the analysis of sequences selected from a library constituted by the protein group, by histidine residues. These substitutions may be combined.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: July 5, 2016
    Assignee: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY
    Inventors: Shinya Honda, Hideki Watanabe, Masayuki Tsukamoto
  • Patent number: 9376470
    Abstract: Novel polypeptides which have an excellent angiogenesis-inducing activity and an excellent antibacterial activity and medical uses thereof are disclosed. The amino acid sequences of the novel polypeptides are shown in any one of SEQ ID NOs:1 to 6. These polypeptides have angiogenesis-inducing and antibacterial activities. Such polypeptides are useful for the prevention, amelioration or treatment of skin wounds caused by a cut wound, surgical wound, erosion, burn, decubitus, intractable wound, skin ulcer, leg ulcer, diabetic ulcer, occlusive arterial disease or arteriosclerosis obliteran, and for the prevention, amelioration or treatment of bacterial infection in such skin wounds, and the like.
    Type: Grant
    Filed: November 27, 2009
    Date of Patent: June 28, 2016
    Assignee: FunPep Inc.
    Inventors: Takefumi Gemba, Hideki Tomioka, Ryoko Sata, Nao Tamura, Akito Maeda, Toshihide Kanamori, Yoshimi Saito, Shintaro Komaba, Ryuichi Morishita
  • Patent number: 9365622
    Abstract: Disclosed are compositions and methods for cyclization of polymers such as peptides.
    Type: Grant
    Filed: March 1, 2007
    Date of Patent: June 14, 2016
    Assignee: University of Utah Research Foundation
    Inventors: Eric W. Schmidt, Brian Hathaway, James T. Nelson, Mohamed S. Donia
  • Patent number: 9353148
    Abstract: The present invention provides a production method of a protected amino acid, protected peptide or peptide, including precipitation and solid-liquid separation of C-protected amino acid or C-protected peptide in a solvent containing water-containing acetonitrile, after removing the N-terminal protecting group from N-protected C-protected amino acid or N-protected C-protected peptide wherein the C-terminal carboxy group is protected by an anchor group.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: May 31, 2016
    Assignee: AJINOMOTO CO., INC.
    Inventor: Daisuke Takahashi
  • Patent number: 9353151
    Abstract: An HLA-binding peptide binding to a HLA-A type molecule, the HLA-binding peptide includes at least one type of amino acid sequence selected from the group consisting of SEQ ID NOS: 1 to 80, and consists of not less than 8 and not more than 11 amino acid residues. All of these amino acid sequences herein mentioned are the predicted amino acid sequences binding to a human HLA-A type molecule with the prediction program using the certain active learning method.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: May 31, 2016
    Assignees: NEC CORPORATION, KOCHI UNIVERSITY
    Inventors: Tomoya Miyakawa, Keiko Udaka
  • Patent number: 9353155
    Abstract: A cell-penetrating peptide is described. Also described is a pro-apoptotic agent including the cell-penetrating peptide and a pro-apoptotic peptide linked thereto. The pro-apoptotic agent is useful for inhibition of in vitro cell proliferation and for treatment of tumors.
    Type: Grant
    Filed: December 27, 2012
    Date of Patent: May 31, 2016
    Assignees: Universite Pierre et Marie Curie (Paris 6), Institute Curie
    Inventors: Angelita Rebollo Garcia, Fariba Nemati, Didier Decaudin, Jeronimo Bravo Sicilia, Jesus Maria Fominaya Gutierrez
  • Patent number: 9328153
    Abstract: The invention relates to polypeptides comprising an N-terminal portion and a C-terminal portion, wherein said N-terminal portion comprises the signature sequence QGP[P or L] and the amino acid sequence of said C-terminal portion is at least 70% identical to SEQ ID NO: 1, and uses thereof.
    Type: Grant
    Filed: June 4, 2013
    Date of Patent: May 3, 2016
    Assignee: Mintaka Foundation for Medical Research
    Inventor: Oliver Hartley
  • Patent number: 9310383
    Abstract: This invention is a selective A? oligomer kit and immunoassay method capable of reliably and sensitively detecting A? oligomers in a biological sample of a patient. In one embodiment the inventive assay uses a pair of anti-A? oligomer antibodies, as capture and detection antibodies, to detect and quantify A? oligomers. The method can be used to differentiate Alzheimer's disease (AD) patients from non-AD patients and/or to stratify AD patients according to the severity of their disease.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: April 12, 2016
    Assignees: Acumen Pharmaceuticals, Inc., Merck Sharp & Dohme Corp.
    Inventors: William F. Goure, Renee C. Gaspar, Alexander McCampbell, Mary J. Savage, Paul J. Shughrue, Fubao Wang, Weirong Wang, Abigail L. Wolfe, Ningyan Zhang, Wei-Qin Zhao, Min Xu
  • Patent number: 9301999
    Abstract: Provided herein are peptides that have activity as mast cell activating proteins (MCAP), as well as compositions, adjuvant compositions, vaccines, and pharmaceutical formulations that include the peptides. Also provided are methods of using the peptides, including methods for eliciting an immune response to an immunogen in a mammal upon administration.
    Type: Grant
    Filed: September 28, 2010
    Date of Patent: April 5, 2016
    Assignee: Duke University
    Inventors: Herman F. Staats, Soman N. Abraham, Salvatore Pizzo
  • Patent number: 9295735
    Abstract: Convection-enhanced delivery (CED) is used as a method to deliver a direct infusion of therapeutic agents to the central nervous center thus circumventing the blood-blood barrier. A non-PEGylated liposomal composition comprising at least one saturated neutral phospholipid and at least one saturated anionic phospholipid and a therapeutic or diagnostic agent encapsulated therein is used to overcome toxicity associated with high peak drug concentration delivered locally CED as well as to increase tissue distribution volume for an improved sustained drug release. In one embodiment, the liposome composition comprises a molar ratio of DSPC:DSPG:CHOL of 7:2:1 and the therapeutic or diagnostic agent is selected from topotecan, conotoxin, gadodiamide or rhodamine, and is used in the treatment of epilepsy.
    Type: Grant
    Filed: November 23, 2009
    Date of Patent: March 29, 2016
    Assignee: MEDGENESIS THERAPEUTIX, INC.
    Inventors: Thomas Redelmeier, Matthias Luz
  • Patent number: 9278122
    Abstract: The present invention provides methods and compositions designed for treating a subject suffering from skin conditions, disorders or diseases. The compositions include fetal skin cell proteins obtained from fetal skin cells after induced cell lysis.
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: March 8, 2016
    Assignee: MERZ GMBH & CO. KGAA
    Inventors: Lee Laurent-Applegate, Patrick Hohlfeld
  • Patent number: 9278128
    Abstract: Compositions, recombinant vaccines and live attenuated pathogens comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with an isolated nucleic acid molecule that encodes IL-15Ra or a functional fragment thereof are disclosed. Methods of inducing an immune response in an individual against an immunogen, using such compositions are disclosed.
    Type: Grant
    Filed: January 6, 2014
    Date of Patent: March 8, 2016
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: David B. Weiner, Kimberly A. Kraynyak, Michele Kutzler
  • Patent number: 9265845
    Abstract: Engineered peptides that bind with high affinity (low equilibrium dissociation constant (Kd)) to the cell surface receptors of fibronectin (?5?1) or vitronectin (?v?3 and ?v?5 integrins) are disclosed as useful as imaging tissue. These peptides are based on a molecular scaffold into which a subsequence containing the RGD integrin-binding motif has been inserted. The subsequence (RGD mimic) comprises about 9-13 amino acids, and the RGD contained within the subsequence can be flanked by a variety of amino acids, the sequence of which was determined by sequential rounds of selection (in vitro evolution). The molecular scaffold is preferably based on a knottin, e.g., EETI (Trypsin inhibitor 2 (Trypsin inhibitor II) (EETI-II) [Ecballium elaterium (Jumping cucumber)], AgRP (Agouti-related protein), and Agatoxin IVB, which peptides have a rigidly defined three-dimensional conformation. It is demonstrated that EETI tolerates mutations in other loops and that the present peptides may be used as imaging agents.
    Type: Grant
    Filed: September 16, 2013
    Date of Patent: February 23, 2016
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Jennifer R. Cochran, Richard Kimura, Sanjiv S. Gambhir, Zhen Cheng
  • Patent number: 9243048
    Abstract: The genes the expression of which is reduced or disappeared in immortal cells including cancer cells are isolated, their DNA sequences are determined, the genes are expressed to produce cell proliferation inhibitory proteins, and the genes and the proteins are utilized as agents for diagnosis or treatment, including the genetic diagnosis of or the gene therapy of diseases such as cancer.
    Type: Grant
    Filed: January 12, 2009
    Date of Patent: January 26, 2016
    Inventors: Masayoshi Namba, Toshiya Tsuji